DHGWA
REGN icon

Dixon Hughes Goodman Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3K Hold
5
– – ﹤0.01% 689
2021
Q4 		$3K Buy
+5
New +$3.07K ﹤0.01% 644

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's REGN Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2022 at 5 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Dixon Hughes Goodman Wealth Advisors first reported a position in REGN in Q4 2021 and has held it in 2 quarters since. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 5 shares of Regeneron Pharmaceuticals worth $3K as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2022.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #689 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.